GC Green Cross Administers First Participant Dose in Phase 1 Clinical Trial of COVID-19 mRNA Vaccine
COVID-19 Vaccine Development Progressing Smoothly Using Proprietary mRNA Platform
GC Green Cross announced on January 30 that it has completed the first dose administration for a participant in the domestic Phase 1 clinical trial of its COVID-19 mRNA vaccine candidate, 'GC4006A'.
GC Green Cross received approval for its Phase 1 IND (Investigational New Drug) application from the Ministry of Food and Drug Safety in December of last year. In this trial, the company is evaluating the safety and immunogenicity of the vaccine in healthy adults aged 19 to 64.
Exterior view of GC Green Cross headquarters in Yongin, Gyeonggi Province. GC Green Cross
View original imageGC4006A is a vaccine candidate developed based on GC Green Cross's proprietary mRNA platform. In preclinical studies, it demonstrated the potential for further development by showing antibody production and immune responses at levels comparable to existing commercial vaccines.
The company explained that, based on the results of the Phase 1 clinical trial, it plans to apply for a Phase 2 IND in the second half of this year.
Jaeuk Jung, Head of R&D at GC Green Cross, stated, "The launch of our first clinical trial for a vaccine utilizing our mRNA platform is highly significant. We will thoroughly verify its safety and efficacy to ensure the successful development of the vaccine."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Meanwhile, in December of last year, GC Green Cross was selected as a company to receive research support for its Phase 1 clinical trial under the 'Pandemic Preparedness mRNA Vaccine Development Support Project' organized by the Korea Disease Control and Prevention Agency and the Korea Health Industry Development Institute. The company continues its research efforts to develop a domestically produced mRNA vaccine.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.